Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

1463508

USP

Nifedipine

United States Pharmacopeia (USP) Reference Standard

Synonyma:

1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C17H18N2O6
Číslo CAS:
21829-25-4
Molekulová hmotnost:
346.33
EC Number:
244-598-3
MDL number:
MFCD00057326
UNSPSC Code:
41116107
PubChem Substance ID:
329750558
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nifedipine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OC

InChI

1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3

InChI key

HYIMSNHJOBLJNT-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

Application

Nifedipine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Nifedipine Capsules
  • Nifedipine Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Related product

Č. produktu
Popis
Stanovení ceny

N0750000

Nifedipine, European Pharmacopoeia (EP) Reference Standard

N0750010

Nifedipine impurity A, European Pharmacopoeia (EP) Reference Standard

1463600

Nifedipine Nitrophenylpyridine Analog, United States Pharmacopeia (USP) Reference Standard

N0750015

Nifedipine impurity B, European Pharmacopoeia (EP) Reference Standard

1463701

Nifedipine Nitrosophenylpyridine Analog, United States Pharmacopeia (USP) Reference Standard

BP462

Nifedipine, British Pharmacopoeia (BP) Reference Standard

BP866

Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)-3,5-pyridinedicarboxylate, British Pharmacopoeia (BP) Reference Standard

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

P D Henry et al.
The Journal of clinical investigation, 68(5), 1366-1369 (1981-11-01)
We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions
Stability studies on nifedipine tablets using thermogravimetry and differential scanning calorimetry.
Franco, P. I. B. M., E. C. Conceic?o, and M. I. G. Leles.
Journal of Thermal Analysis and Calorimetry, 93.2, 381-385 (2008)
P D Henry
The American journal of cardiology, 46(6), 1047-1058 (1980-12-01)
Calcium antagonists (slow channel blocking agents) are a very heterogeneous group of agents with dissimilar structural, electrophysiologic and pharmacologic properties. Nifedipine is a potent, long-acting vasodilator that has proved highly efficacious in relieving anginal symptoms caused by coronary vasospasm. In
Corey B Toal et al.
Blood pressure, 21 Suppl 1, 3-10 (2012-07-06)
Calcium-channel blockers (CCBs) constitute a diverse group of compounds but are often referred to as a single homogeneous class of drug and the clinical responses indiscriminately summarized. Even within the dihydropyridine subgroup, there are significant differences in formulations, pharmacokinetics, durations
Ryuichi Morishita et al.
Drugs, 66 Spec No 1, 31-33 (2008-01-19)
Useful drug therapy for inhibiting the extension of an aortic aneurysm or promoting its involution has not yet been established. Hypertension is a known risk factor for extension of an aortic aneurysm. However, on a cellular level it is believed
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.